Postmenopausal women who received hormone therapy for one year, with either estrogen alone or estrogen plus progesterone, experienced a drop in certain metabolites, such as C3-carnitine, C5-carnitine and glycine, compared with those on hormone therapy and placebo, researchers reported at the North American Menopause Society annual meeting. Researchers used a cohort of 1,072 women and found that those ages 70 to 79 who took estrogen plus progesterone showed the strongest association between hormone therapy and metabolites compared with those ages 50 to 59, who had the weakest association, and that women who take hormone therapy see less of a progression to type 2 diabetes.
Hormone therapy may reduce diabetes risk in postmenopausal women
Sign up for DiabetesPro SmartBrief
News for diabetes health professionals
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.